Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Dilantin (phenytoin) Supplemental Approval Letter
Correction: quantitative detection of epstein-barr virus DNA in cerebrospinal fluid and blood samples of patients with relapsing-remitting multiple sclerosis.
The multiple sclerosis relapse experience: patient-reported outcomes from the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry.
Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
Human Endogenous Retrovirus K(HML-2) Gag and Env specific T-cell responses are not detected in HTLV-I-infected subjects using standard peptide screening methods.
Survey results show that adults are willing to pay higher insurance premiums for generous coverage of specialty drugs.
CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation.
Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study.
Non-steroidal anti-inflammatory drug indometacin enhances endogenous remyelination.
[Central motor pathways in children with multiple sclerosis].
A2A Adenosine Receptor Signaling in Lymphocytes and the Central Nervous System Regulates Inflammation during Experimental Autoimmune Encephalomyelitis.
Differences in Diffusion Tensor Imaging-Derived Metrics in the Corpus Callosum of Patients With Multiple Sclerosis Without and With Gadolinium-Enhancing Cerebral Lesions.
Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients.
Psychiatric disorders in patients with multiple sclerosis.
Age-specific sex ratio of multiple sclerosis in the National Swedish MS Register (SMSreg).
Secukinumab shines in small MS trial
Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis.
The Transcription Factor IRF8 Activates Integrin-Mediated TGF-β Signaling and Promotes Neuroinflammation.
Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4(+) T Cells of Patients with Relapsing-Remitting Multiple Sclerosis.
Inpatient Rehabilitation Utilization for Medicare Beneficiaries with Multiple Sclerosis.
Immunomodulators for multiple sclerosis may ameliorate spinal bone loss.
In vivo vs. ex vivo Magnetic Resonance Imaging In Mice.
Potential role of OPG/RANKL system and FokI genotypes in pathogenesis and clinical manifestations in multiple sclerosis.
Quality of Life Assessment in Patients with Multiple Sclerosis Receiving Interferon Beta-1a: A Comparative Longitudinal Study of Avonex and Its Biosimilar CinnoVex.
Assessment of changes in immune measures of multiple sclerosis patients treated with laquinimod.

Pages